• Dharma Therapeutics (Seattle) said that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, has demonstrated safety and efficacy in a Phase 2 clinical trial. The trial evaluated the safety and efficacy of the administration of lidocaine and epinephrine using the company's Iontophoretic Drug Delivery System (IDDS) to provide topical anesthesia in adults undergoing a venipuncture procedure. Subjects were randomized to receive an 8-minute administration of lidocaine plus epinephrine (active group) or epinephrine alone (placebo group) at the site of insertion of an intravenous catheter. After placement of the intravenous catheter, subjects evaluated their pain using the Visual Analog pain Scale (VAS) scoring system and were asked if they would use the IDDS again. The trial demonstrated statistically lower VAS scores for the Active group as compared to the Placebo group. The IDDS treatment was well tolerated, with no serious adverse event reported in any subject.

• Dossia (Cambridge, Massachusetts) reported a new application programming interface (API) for its personally controlled health record (PCHR) platform. The new API provides for secure authorization and access to a participant's health data, and supports Dossia's ecosystem partners, which include MediKeeper, Metavante, HealthTrio, eClinicalWorks as well as others from the National Coalition of Health Integration. The core technologies used by the API include: OpenID, which enables shared identity with Dossia's ecosystem partners across web sites; OAuth, an open protocol to allow secure API authorization; and Representational State Transform (REST), which provides for a simple access method for reading and updating health data.

Medtronic (Minneapolis) said that it has initiated a recall of specific lots of Quick-set infusion sets that are used with MiniMed Paradigm insulin pumps. An infusion set is a thin plastic tube used to deliver insulin from an insulin pump to a diabetes patient, and is typically replaced by the patient every three days. Affected infusion sets are reference numbers MMT-396, MMT-397, MMT-398 and MMT-399 with lot numbers starting with the number "8." Medtronic recently discovered that approximately 2% of "Lot 8" Quick-set infusion sets (which represents approximately 60,000 infusion sets out of an estimated 3 million infusion sets currently with customers) may not work properly. The affected infusion sets may not allow the insulin pump to vent air pressure properly. This could potentially result in the device delivering too much or too little insulin and may lead to serious injury or death.